BPC-157 — 5mg
109.99€
Tirzepatide — 20mg
The dual GIP/GLP-1 agonist that outperformed semaglutide in every head-to-head clinical trial.
329.99€
Price per vial · Ex Tax 329.99€
- In Stock
- Evidence tier: Established
- Format: Lyophilized
- Purity: 99.6%
- Vial size: 20mg
For laboratory research use only. Not for human or veterinary use.
About Tirzepatide
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that has become one of the most studied peptides in modern metabolic research. It simultaneously targets two incretin pathways, making it a subject of intense scientific interest for its role in glucose metabolism and body composition. Researchers continue to investigate its unique dual mechanism, which distinguishes it from single-agonist compounds.
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist that has become one of the most studied peptides in modern metabolic research. It simultaneously targets two incretin pathways, making it a subject of intense scientific interest for its role in glucose metabolism and body composition. Researchers continue to investigate its unique dual mechanism, which distinguishes it from single-agonist compounds.
Tirzepatide is a 39-amino acid acylated peptide with a C20 fatty diacid moiety enabling once-weekly dosing. It acts as an imbalanced dual agonist: full potency at the GIP receptor (equal affinity to native GIP) and approximately 5-fold weaker affinity at the GLP-1 receptor vs native GLP-1. This imbalanced pharmacology drives unique signaling bias. Activates cAMP accumulation through both GIPR and GLP-1R, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing food intake via central appetite circuits.
Mechanism clarity: Well-characterized
Tags
Key takeaways
-
Research score 10/10
5,000+ published studies in the dataset
-
Evidence tier: Established
Established — Robust Phase 3 data (SURPASS 1-5, SURMOUNT 1-4), FDA-approved as Mounjaro (T2D) and Zepbound (obesity). Thousands of participants across RCTs.
-
Human data
Large RCTs (thousands of participants)
Storage and handling
Lyophilised powder: Room temp or refrigerated
After reconstitution: Refrigerate, use within 30 days
Reconstitution steps from the dataset
- Clean. Remove flip-top cap from tirzepatide vial and swab rubber stopper with alcohol.
- Draw water. Draw 2mL of bacteriostatic water into syringe.
- Inject water. Insert needle through stopper and slowly inject water down the side of the vial. Do not spray directly onto powder.
- Dissolve. Gently swirl (do not shake) until fully dissolved. Solution should be clear.
- Label. Label vial with date and concentration (5mg/mL). Refrigerate immediately.
- Dose. For 2.5mg dose: draw 0.5mL (50 units). For 5mg dose: draw 1.0mL (100 units). Inject subcutaneously once weekly.
Safety and limitations
Studied for: Weight loss, Type 2 diabetes, Metabolic syndrome, Appetite suppression, Body recomposition
Reported onset: 1-2 weeks for appetite suppression; 4-8 weeks for significant weight loss
Reported duration: Ongoing; dose escalation over 4-week intervals from 2.5mg to 15mg
Community reports: Nausea common in first 2-4 weeks at each dose escalation, usually subsides. Most users report 1-2 lbs/week loss. Weight regain documented in 82% upon cessation.
For research and educational use only. Source values are reproduced from the current PeptidesEuro content dataset and are not medical advice.
Quality and specifications
Product details
- Product code
- L-TIRZ-20
- Availability
- In Stock
- Evidence tier
- Established
- Format
- Lyophilized
- Purity
- 99.6%
- Vial size
- 20mg
Reconstitution reference
- Bacteriostatic water
- 2 mL
- Concentration
- 5mg/mL when reconstituted with 2mL. 2.5mg dose = 0.5mL (50 units on insulin syringe).
- Syringe
- 29-31G insulin syringe
Research parameters
- Standard amount
- 2500 µg
- Alternative amount
- 5000 µg
- Vial
- 10 mg
- Dataset estimate
- 1 vial lasts 4 weeks at 2.5mg/week
Lab report record
- Laboratory
- Janoshik Analytical
- Test date
- 2026-03-01
- Document
- PDF not attached
See the science
-
PMID 33325008
Read study: The Role of Tirzepatide in Management of T2D: SURPASS Trials (opens in a new tab)
The Role of Tirzepatide in Management of T2D: SURPASS Trials
39-amino acid synthetic peptide; dose-dependent weight loss up to 12.4%
-
PMID 36050763
Read study: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for T2D (opens in a new tab)
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for T2D
First dual agonist approved; superior HbA1c and weight reduction vs semaglutide
-
PMID 37385275
Read study: Tirzepatide for obesity in adults without diabetes (opens in a new tab)
Tirzepatide for obesity in adults without diabetes
Up to 22.5% body weight loss at 15mg dose over 72 weeks
Studies are listed for reference. Most were carried out in animal or cell models; their findings do not establish safety or effect in humans.
Further reading
Community evidence
- Source window English Reddit Updated 13 Aug 2026 · 2-year window
- Coverage confidence Low Confidence in the available community sample
- Distribution Pending Not enough data for a distribution.
Selected reports
-
6 months agor/TirzepatideRX · Post
I started tirzepatide this past Friday at 2.0 mg. … Immediately, I was already feeling the effects, specifically with the appetite suppression.
-
8 months agor/glp1 · Post
Hey everyone, I'm about 4 months into my tirzepatide journey and wanted to share what I've learned. I'm 42, started at 240, and I'm down 45 pounds as of this week. This stuff works, but there's a lot they don't tell you. First, the good stuff: The weight loss is real. I'm
-
10 months agor/PMDD · Post
About two months ago, I started tirzepatide at a very low dose (2.5 mg) for reasons unrelated to PMDD. … I’m not exaggerating when I say I’ve had a ~95% improvement in quality of life.
Based on 4 qualifying reports from 4 threads. 37 candidates excluded as duplicates, promotion, deleted content, or lacking concrete personal experience. Reddit self-reports are not medical evidence or proof of causation.
Questions about Tirzepatide
Questions and answers recorded for this product.
Clinical data shows weight regain in approximately 82% of participants after discontinuation. Most researchers view it as an ongoing protocol rather than a short cycle.
Tirzepatide is the active compound. Mounjaro is the brand name for type 2 diabetes, Zepbound for obesity. Research-grade tirzepatide is the same molecule.
Tirzepatide is a dual agonist (GIP + GLP-1) while semaglutide targets only GLP-1. Clinical trials show tirzepatide produces roughly 50% more weight loss. It also tends to have a different side effect profile.
Reviews
There are no reviews for this product yet.
Related products
-
-
MOTS-c — 10mg
189.99€
-
Tirzepatide — 10mg
189.99€
-
Retatrutide — 10mg
289.99€
-
Tesamorelin — 10mg
279.99€
How ordering works
Product details, references and your order stay connected.
-
Choose the compound
Pick a compound and vial size in the catalogue.
-
Review product information
Open the product details and supporting research.
-
Keep the references
Save the source references for your records.
Why order from PeptidesEuro
Compound profiles
Structure, available sizes and handling notes on one record.
Study references
Product pages link to the studies behind each compound.
One order record
Orders and their details stay in your account.
Clear product data
Price, stock status and tax shown on every product.
PeptidesEuro is a research materials supplier operated by Pepticore LLC. We provide high-purity peptides and research compounds for in-vitro laboratory and scientific research purposes. All products are sold strictly for research use only and are not intended for human or animal consumption.
No. All products sold through meimx.com are intended strictly for in-vitro laboratory and scientific research purposes only. They are not intended for human or animal consumption, injection, ingestion, inhalation, or any form of administration to living organisms. By purchasing from PeptidesEuro, you acknowledge and agree to these terms as outlined in our Terms of Service.
No. Our products have not been evaluated, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. They are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. PeptidesEuro is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
No. PeptidesEuro does not provide medical advice, treatment recommendations, or dosing instructions. Any information on our website, including product descriptions and referenced research, is provided for educational and informational purposes only. If you have medical questions, please consult a licensed healthcare provider.
Research Use Only means that our products are sold exclusively as reference standards and research materials for use in laboratory and scientific research settings. Purchasers agree to use all products solely for legitimate research purposes in compliance with all applicable laws and regulations.
Ready to order Tirzepatide?
Browse the catalogue or answer one question in the product finder.